JP7092776B2 - ｃｒｍｐ２のＳＵＭＯ関連修飾の小分子拮抗物質及びその使用 - Google Patents

ｃｒｍｐ２のＳＵＭＯ関連修飾の小分子拮抗物質及びその使用 Download PDF

Info

Publication number
JP7092776B2
JP7092776B2 JP2019542201A JP2019542201A JP7092776B2 JP 7092776 B2 JP7092776 B2 JP 7092776B2 JP 2019542201 A JP2019542201 A JP 2019542201A JP 2019542201 A JP2019542201 A JP 2019542201A JP 7092776 B2 JP7092776 B2 JP 7092776B2
Authority
JP
Japan
Prior art keywords
mmol
crmp2
added
benzo
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505434A (ja
JP2020505434A5 (https=
Inventor
カーナ，メイ
カーナ，ラジェシュ
ゴカーレ，ヴィジェイ
チャウラ，リーナ
Original Assignee
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ filed Critical アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ
Publication of JP2020505434A publication Critical patent/JP2020505434A/ja
Publication of JP2020505434A5 publication Critical patent/JP2020505434A5/ja
Application granted granted Critical
Publication of JP7092776B2 publication Critical patent/JP7092776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019542201A 2017-02-03 2018-02-02 ｃｒｍｐ２のＳＵＭＯ関連修飾の小分子拮抗物質及びその使用 Active JP7092776B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762454475P 2017-02-03 2017-02-03
US62/454,475 2017-02-03
US201762506298P 2017-05-15 2017-05-15
US62/506,298 2017-05-15
PCT/US2018/016687 WO2018144900A1 (en) 2017-02-03 2018-02-02 Small molecule antagonists of sumo related modification of crmp2 and uses thereof

Publications (3)

Publication Number Publication Date
JP2020505434A JP2020505434A (ja) 2020-02-20
JP2020505434A5 JP2020505434A5 (https=) 2021-04-15
JP7092776B2 true JP7092776B2 (ja) 2022-06-28

Family

ID=63041159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542201A Active JP7092776B2 (ja) 2017-02-03 2018-02-02 ｃｒｍｐ２のＳＵＭＯ関連修飾の小分子拮抗物質及びその使用

Country Status (7)

Country Link
US (1) US11208397B2 (https=)
EP (1) EP3576734A4 (https=)
JP (1) JP7092776B2 (https=)
CN (1) CN110381941A (https=)
AU (1) AU2018215466B2 (https=)
CA (1) CA3052195A1 (https=)
WO (1) WO2018144900A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129167A1 (en) * 2023-12-15 2025-06-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Inhibitors of the surface expression of the voltage-gated sodium ion channel 1.7 (nav1.7) and their therapeutic uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512372A (ja) 1999-10-18 2003-04-02 スミスクライン ビーチャム パブリック リミテッド カンパニー テトラヒドロベンゾインドロン誘導体、それらの製造および５−ｈｔ７受容体アンタゴニストとしてのそれらの使用
CN102627631A (zh) 2012-03-31 2012-08-08 中国药科大学 苯并杂环类化合物、其制备方法及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
EP2240464A4 (en) * 2008-02-12 2011-09-14 Yuhan Corp PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE PRODUCTS
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
US9828348B2 (en) * 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
EP3119415A4 (en) 2014-03-07 2017-11-29 The Arizona Board of Regents on behalf of the University of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途
EP3359151A4 (en) * 2015-10-07 2019-08-14 Arizona Board of Regents on behalf of the University of Arizona CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512372A (ja) 1999-10-18 2003-04-02 スミスクライン ビーチャム パブリック リミテッド カンパニー テトラヒドロベンゾインドロン誘導体、それらの製造および５−ｈｔ７受容体アンタゴニストとしてのそれらの使用
CN102627631A (zh) 2012-03-31 2012-08-08 中国药科大学 苯并杂环类化合物、其制备方法及其医药用途

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Chemical Biology & Drug Design，2015年，Vol.86, No.4，pp.509-516
REGISTRY（STN）[on line]，2005年02月24日，[検索日 2021.11.02], CAS登録番号 836691-50-0
REGISTRY（STN）[on line]，2005年02月24日，[検索日 2021.11.02], CAS登録番号 836691-52-2
REGISTRY（STN）[on line]，2007年04月30日，[検索日 2021.11.02], CAS登録番号 933704-38-2
REGISTRY（STN）[on line]，2009年05月19日，[検索日 2021.11.02], CAS登録番号 1147323-08-7
REGISTRY（STN）[on line]，2012年04月15日，[検索日 2021.11.02], CAS登録番号 1368488-37-2
REGISTRY（STN）[on line]，2012年08月12日，[検索日 2021.11.02], CAS登録番号 1389137-38-5
REGISTRY（STN）[on line]，2012年08月13日，[検索日 2021.11.02], CAS登録番号 1390430-30-4
REGISTRY（STN）[on line]，2013年02月14日，[検索日 2021.11.02], CAS登録番号 1420816-71-2

Also Published As

Publication number Publication date
EP3576734A4 (en) 2020-12-09
EP3576734A1 (en) 2019-12-11
CA3052195A1 (en) 2018-08-09
CN110381941A (zh) 2019-10-25
AU2018215466A1 (en) 2019-08-22
WO2018144900A1 (en) 2018-08-09
US20200277271A1 (en) 2020-09-03
JP2020505434A (ja) 2020-02-20
AU2018215466B2 (en) 2022-03-10
US11208397B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
JP7472103B2 (ja) トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
JP6047563B2 (ja) 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の治療におけるその使用
TWI511730B (zh) σ配位體在類鴉片引發之痛覺過敏上的用途
KR101855358B1 (ko) 골암통증에서의 시그마 리간드의 용도
RS54998B1 (sr) Antagonisti c5ar
KR20190133047A (ko) Mor 작용제 및 kor 작용제를 함유하는 약학적 조성물, 및 그의 용도
EP2646435B1 (en) 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
JP2016523276A (ja) 間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用
JP2016516792A (ja) α−２アドレノレセプターおよびシグマレセプターリガンドの組み合わせ物
AU2017233716B2 (en) Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
EP3597634B1 (en) Oxygenated ammonium-containing sulfonic acids and their medical use
JP7092776B2 (ja) ｃｒｍｐ２のＳＵＭＯ関連修飾の小分子拮抗物質及びその使用
US20260083704A1 (en) Lxr modulators with bicyclic core moiety for treating dyslipidemias
EP2305645A1 (en) Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
US11299476B2 (en) Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
WO2025215201A1 (en) Pannexin-1 inhibitors and uses thereof
JP2025507902A (ja) ヒスタミンｈ３受容体阻害剤及びその医薬における使用
CN107849033A (zh) 用于治疗Rac‑GTP酶介导的病症的化合物
EA052086B1 (ru) Антагонисты рецептора гистамина h3 и их фармацевтическое применение
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
EA044762B1 (ru) Фенилтриазольный ингибитор белок-белковых взаимодействий mll1-wdr5
HK1190145B (en) 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220616

R150 Certificate of patent or registration of utility model

Ref document number: 7092776

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250